Krystal Biotech, Inc.
For the period ended Sep 30, 2025. Filed Nov 3, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 3, 2025
KRYS$306.50+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of and
Condensed Consolidated Balance Sheets
| (in thousands, except par value) | September 30,2025 | December 31,2024 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $392,604 | $344,865 |
| Short-term investments | 338,465 | 252,652 |
| Accounts receivable, net | 129,633 | 104,746 |
| Inventory | 37,632 | 26,508 |
| Prepaid taxes | 10,103 | 1,617 |
| Prepaid expenses and other current assets | 17,213 | 11,657 |
| Total current assets | 925,650 | 742,045 |
| Property and equipment, net | 148,871 | 155,168 |
| Long-term investments | 133,113 | 152,114 |
| Right-of-use assets | 7,447 | 6,280 |
| Deferred tax asset, net of valuation allowance | 24,680 | — |
| Other non-current assets | 333 | 231 |
| Total assets | $1,240,094 | $1,055,838 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $2,097 | $4,985 |
| Current portion of lease liability | 1,698 | 1,217 |
| Accrued rebates | 55,769 | 36,804 |
| Accrued expenses and other current liabilities | 31,704 | 58,989 |
| Total current liabilities | 91,268 | 101,995 |
| Lease liability | 7,813 | 6,044 |
| Other long-term liabilities | 3,137 | 1,419 |
| Total liabilities | 102,218 | 109,458 |
| Commitments and contingencies (see note 7) | ||
| Stockholders’ equity | ||
| Common stock; $0.00001 par value; 80,000 shares authorized as of September 30, 2025 and December 31, 2024; 28,984 and 28,794 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively. | — | — |
| Additional paid-in capital | 1,164,013 | 1,127,238 |
| Accumulated other comprehensive gain (loss) | 1,100 | (190) |
| Accumulated deficit | (27,237) | (180,668) |
| Total stockholders’ equity | 1,137,876 | 946,380 |
| Total liabilities and stockholders’ equity | $1,240,094 | $1,055,838 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.